F2G Ltd Appoints Ian Nicholson as Chief Executive Officer.
Dr Richard White, Executive Chairman of F2G, commented, "We are delighted to welcome such an experienced executive to lead the company, and I look forward to working closely with him." Dr. White will revert to his former role of Non-Executive Chairman. Ian Nicholson added, "I am excited to join F2G at this critical stage and lead the company in the successful development of an important first-in-class drug to treat Aspergillosis, an area of high unmet medical need."
About F2G Ltd: Based in Manchester, UK, F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. This is a growing health risk for which there are currently limited treatment options and for which demand is increasing globally. Market growth is expected to increase with the emergence of new clinical indications in allergies and asthma. For more information visit www.f2g.com
+44 161 785 1271
Contact via Email
|Printer friendly Cite/link Email Feedback|
|Publication:||PR.com (Press Releases)|
|Date:||Mar 20, 2013|
|Previous Article:||Hackensack University Medical Center - Department of Medicine Chooses SpectraMedi, the Top Transcription Service Provider in U.S.|
|Next Article:||GL Announces MAPS[TM] GPRS Gb Interface Emulator.|